Cerebral

Cerebral was founded in 2019 by Kyle Robertson, growing very rapidly during the COVID-19 pandemic as demand for accessible telehealth mental health services surged and in-person psychiatric and therapy appointments became harder to access, offering online mental health assessments, therapy sessions, and, notably, medication management services that could prescribe psychiatric medications, including stimulant medications used to treat attention deficit hyperactivity disorder (ADHD), through a fully virtual model. The company's rapid growth and aggressive direct-to-consumer marketing, alongside a business model that some critics argued incentivized prescribers to write prescriptions quickly to support subscription retention, drew significant scrutiny starting in 2022. Cerebral came under investigation by the U.S. Department of Justice and the Drug Enforcement Administration over concerns that its prescribing practices for stimulant medications may have violated federal rules around telehealth prescribing of controlled substances, particularly rules that had been temporarily relaxed during the COVID-19 public health emergency to expand telehealth access, and the company faced a wave of negative media coverage, including reporting alleging that some clinicians felt pressured to prescribe stimulants quickly to meet patient demand and subscription targets. In response to this scrutiny, Cerebral announced it would stop prescribing controlled substances like Adderall for new ADHD patients, its founder and CEO Kyle Robertson departed the company, and the company conducted significant layoffs and restructuring as it worked to address the regulatory concerns and rebuild trust. Cerebral ultimately reached settlements related to the investigations, including agreeing to pay tens of millions of dollars to resolve federal claims related to improper billing and prescribing practices. The episode became a widely cited cautionary case study regarding the risks of the rapid, venture-funded telehealth prescribing boom that occurred during the pandemic-era relaxation of controlled substance telehealth rules, and Cerebral has continued operating with a more constrained scope of services and greater compliance oversight following these events.

News

8/5/2025

Cerebral Acquires Resilience Lab to Enhance Integrated Mental Health Services

Cerebral's acquisition of Resilience Lab positions it to deliver comprehensive mental health solutions, potentially reshaping the competitive landscape and enhancing patient outcomes in a rapidly evolving healthcare market.

PR Newswire

Behavioral Health Business

HIT Consultant

3/4/2025

Cerebral CEO David Mou Steps Down, Launches New Mental Health Startup AdvocateMH

David Mou's transition from Cerebral to AdvocateMH signals a strategic shift in the mental health sector, potentially reshaping service delivery and innovation in response to growing demand for accessible mental health solutions.

Business Insider

Endpoints News

Behavioral Health Business

1/20/2025

Cerebral Partners with San Antonio Spurs to Enhance Mental Health Care Access in Texas

Cerebral's partnership with the San Antonio Spurs not only enhances mental health access in Texas but also positions the organization as a leader in integrating wellness into community engagement, potentially influencing similar collaborations nationwide.

Business Wire

11/21/2024

Transformative Advances in Healthcare: AI, Mental Health, and Ethical Challenges Ahead

The integration of AI in healthcare not only enhances patient outcomes but also raises critical ethical questions, potentially reshaping regulatory frameworks and investment strategies in the sector.

Forbes

Nature

11/6/2024

Cerebral Agrees to Pay Over $3.6 Million for Improper Prescription Practices

Cerebral's $3.6 million settlement highlights the increasing scrutiny on telehealth practices, potentially reshaping regulatory standards and consumer trust in digital mental health services.

TechTarget

MedPage Today

Healthcare Dive